What is CHOP?

CHOP is an acronym expressing a combination chemotherapeutic drug regimen used in the treatment of some cancers.

CHOP consists of the following drugs:

  • Cyclophosphamide
  • Hydroxyldaunorubicin (doxorubicin)
  • Oncovin (vincristine)
  • Prednisone

The CHOP regimen

The CHOP regimen is tailored to each individual patient, but is generally administered according to a 21-day cycle.

On day one of the cycle, the patient receives an intravenous infusion of cyclophosphamide, as well as doxorubicin and vincristine by intravenous push. On days one through five, the patient takes prednisone orally (in pill form).

What is CHOP used for?

The CHOP combination chemotherapy regimen used to be used quite commonly for many different subtypes of non-Hodgkin's lymphoma prior to the arrival on the market of the monoclonal antibody rituximab (now, instead of CHOP, B-cell patients tend to receive rituximab plus CHOP, or R-CHOP). However, CHOP may still be used against certain lymphomas such as chronic lymphocytic leukemia (small lymphocytic lymphoma), AIDS-related B-cell lymphoma, and anaplastic large T-cell lymphoma (ALK+). It continues to be used against peripheral T-cell lymphomas other than ALTL (ALK+), but the results are not optimal and a more effective treatment for T-cell lymphomas remains an unmet need in the treatment of T-cell lymphomas.

Does CHOP have side effects?

CHOP causes side effects in most patients who receive the regimen, although not in all patients. Typically, a patient receiving CHOP will experience mouth sores, nausea and/or vomiting, significant but temporary hair loss, and possibly some toxicity issues with major organs, like the liver, lungs and heart.

Although R-CHOP is an improvement over CHOP, in the early 1970s, CHOP itself was an improvement over HOP—the same regimen minus the addition of cyclophosphamide. Doctors and researchers are always looking to increase the efficacy of drug regimens in patients while lowering the toxicity and side effects in patients.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap